Serological markers of tumour (normal range) Pre-treatment AP (pemetrexed cisplatin) +endostatin TP (paclitaxel platinum) +camrelizumab+endostatin camrelizumab+endostatin Camrelizumab+bevacizumaab+endostatin Camrelizumab+bevacizumab
2020/12/22 2021/3/31 2021-04-20 (treatment for malignant pleural effusion) 2021/9/2 2021/12/15 2022/3/30 2022/5/2 2022/7/15 2023/3/15 2023/11/28
IL-6, pg/ml 157.1
SCC (Squamous cell carcinoma-associated antigen), ng/ml (0-1.5 pg/ml) 2.1 0.6 1.2 1.2 4 1 1.3 0.8 1.3 1.6
ProGRP (Gastrin-releasing peptide precursor), pg/ml (25.3-77.8 pg/ml) 43.94 26.43 28 37.1 48.34 36.8 42.69 31.8 32.00 34.05
NSE (Neuron-specific enolase), ng/ml (0-16.3 pg/ml) 42.32 15.52 29.88 9.43 12.79 12.5 11.56 11.45 8.93 13.13
CYFRA211, ng/ml 7.67 3.42 4.08 2.29 3.26 2.25 1.61 2.8 2.59 17.6
CA199, U/mL (0-25 U/mL) 17.7 20.9 20.7 14.4 16.4 15.1 13 17.4 13.6 10.1
CEA (Carcinoembryonic antigen), ng/ml (0-5 ng/ml) 13.43 43.08 33.68 9.3 6.85 14.31 12.83 7.97 10.82 3.82
AFP(Alpha-fetoprotein), ng/ml (0-9 ng/ml) 1.96 6.25 11.4 3.06 3.89 3.32 3.04 3.2 3.05 3.02
CA153, U/mL (0-14 U/mL) 34.5 42.2 11.4 8.1 20.8 22.2 12.9 12.60
CA125, U/mL (0-35 U/mL) 347.3 604.7 51.6 7.4 129.3 134.7 20.7 31.7